Calvin J Kuo

May 15, 2024 | nature.com | Sean A. Yamada-Hunter |Brianna J. McIntosh |Frank Lin |Amaury Leruste |Zinaida Good |Calvin J Kuo | +6 more

AbstractAdoptively transferred T cells and agents designed to block the CD47–SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system1,2. Here we administered anti-CD47 antibodies in combination with adoptively transferred T cells with the goal of enhancing antitumour efficacy but observed abrogated therapeutic benefit due to rapid macrophage-mediated clearance of T cells expressing chimeric antigen receptors (CARs) or engineered T cell receptors.